1-3 of 3
Gisela Tunes da Silva, PhD.
Close
Sort by
Journal Articles

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.

Parameswaran N Hari, MD, A. John Barrett, MD, Smriti Shrestha, MS, MA, Gisela Tunes da Silva, PhD, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Olle Ringden, MD
Journal: Blood
Blood (2009) 114 (22): 53.
https://doi.org/10.1182/blood.V114.22.53.53
Published: 2009
Journal Articles

Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Brian McClune, DO, Daniel J. Weisdorf, MD, John F. DiPersio, MD, PhD, Armand Keating, MD, Tanya L. Pedersen, Gisela Tunes da Silva, PhD., J. Sierra, MD, Martin S. Tallman, MD, Sergio A. Giralt
Journal: Blood
Blood (2008) 112 (11): 346.
https://doi.org/10.1182/blood.V112.11.346.346
Published: 2008
Journal Articles

Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Armand Keating, MD, Manisha Kukreja, MBBS, MPH, Gisela Tunes da Silva, PhD, Vikas Gupta, MD, MRCP, MRCPath, Corey Cutler, MD, MPH, Martin S. Tallman, MD, Jorge Sierra, MD, John F. DiPersio, MD, PhD, Mary M. Horowitz, MD, MS, Daniel J. Weisdorf, MD
Journal: Blood
Blood (2008) 112 (11): 2168.
https://doi.org/10.1182/blood.V112.11.2168.2168
Published: 2008